Zhen Liang, Lingmin Zhao, Yingyue Lou, Songyan Liu
BACKGROUND: Previous studies have reported inconsistent results on the association between circulating lipids and lipid-lowering drugs with the risk of epilepsy. OBJECTIVE: To assess whether genetically predicted circulating lipids and lipid-lowering drugs are causally associated with the risk of epilepsy outcome. METHODS: We performed a two-sample Mendelian Randomization (MR) analysis model to genetically predict the causal effects of circulating lipids (Apolipoprotein A [APOA] Apolipoprotein B [APOB], Cholesterol, High density lipoprotein cholesterol [HDL-C], Low density lipoprotein cholesterol [LDL-C], Lipoprotein A, Triglycerides) and lipid-lowering drugs (HMG-CoA reductase [HMGCR] and Proprotein Convertase Subtilisin/Kexin Type 9 [PCSK9] inhibitors) on epilepsy...
March 25, 2023: QJM: Monthly Journal of the Association of Physicians